Greater Well-Being in More Physically Active Cancer Patients Who Are Enrolled in Supportive Care Services

Maira Tristão Parra, ScD1, Naghmeh Esmeaeli, MD2, Jordan Kohn, PhD1, Brook L. Henry, PhD1, Stephen Klagholz, MS3, Shamini Jain, PhD1, Christopher Pruitt, BS1, Daniel Vicario, MD1, Wayne Jonas, MD2, and Paul J. Mills, PhD1

Abstract

Background: Cancers are one of the leading causes of mortality worldwide. Cancer patients are increasingly seeking integrative care clinics to promote their health and well-being during and after treatment. Aim: To examine relationships between physical activity (PA) and quality of life (QoL) in a sample of cancer patients enrolling in integrative care in a supportive care clinic. Also, to explore circulating inflammatory biomarkers and heart rate variability (HRV) in relationship to PA and QoL. Methods: A cross-sectional design of adult patients who sought care in the InspireHealth clinic, Vancouver, British Columbia, Canada. Patients with complete PA data (n = 118) answered psychosocial questionnaires, provided blood samples, and received HRV recordings before enrollment. Patients were stratified into “less” versus “more” active groups according to PA guidelines (150 minutes of moderate or 75 minutes of vigorous PA or an equivalent combination). Results: Breast (33.1%) and prostate (10.2%) cancers were the most prevalent primary diagnoses. Patients engaging in more PA reported better physical (U = 1265.5, P = .013), functional (U = 1306.5, P = .024), and general QoL (U = 1341, P = .014), less fatigue (U = 1268, P = .014), fewer physical cancer-related symptoms (U = 2.338, P = .021), and less general distress (U = 2.061, P = .021). Between PA groups, type of primary cancer diagnosis differed (χ² = 41.79, P = .014), while stages of cancer did not (χ² = 3.95, P = .412). Fewer patients reported depressed mood within the more active group (χ² = 6.131, P = .047). More active patients were also less likely to have ever used tobacco (χ² = 7.41, P = .025) and used fewer nutritional supplements (χ² = 39.74, P ≤ .001). An inflammatory biomarker index was negatively correlated with vigorous PA (r = −0.215, P = .022). Multivariable linear regression (R² = 0.71) revealed that age (β = 0.22; P = .001), fatigue (β = −0.43; P ≤ .001), anxiety (β = −0.14; P = .048), and social support (β = 0.38; P = .001) were significant correlates of QoL.

Keywords

physical activity, cancer care facilities, quality of life, biomarkers, cross-sectional

Submitted October 3, 2019; revised March 25, 2020; accepted April 2, 2020

Background

Cancer is a generic term for a large group of diseases characterized by abnormal growth of cells, which can invade adjoining parts of the body and spread to other organs.1 Its incidence and mortality have been growing worldwide, and in 2018, new cases were estimated at 18.1 million, causing 9.6 million deaths.2 According to the World Health Organization (WHO), cancers rank among the top 20 disease-related causes of mortality worldwide, specifically tracheal, bronchial, and lung cancers (6th); liver cancer (16th); colorectal cancers (17th); and stomach cancers (18th).3 Among men, lung cancer is the most prevalent type and a
leading cause of cancer deaths, whereas breast cancer is the most prevalent and lethal among women. In Canada, specifically, cancers (ie, malignant neoplasms) are currently the leading cause of death, surpassing mortality due to heart disease and causing more than 79,000 deaths in 2017.

Biomedical advances have improved our understanding of the etiology of various cancers, as well as the development of effective treatments and prevention strategies. Yet, despite these efforts, cancer mortality continues to increase, highlighting the importance of prevention and risk factor mitigation. To that end, the WHO published the 2013 Global Action Plan for the prevention and control of noncommunicable diseases (NCDs), wherein a key objective was “to reduce modifiable risk factors for NCDs and underlying social determinants through the creation of health-promoting environments.” Strategies to prevent cancers and other NCDs include increasing physical activity (PA) levels, reducing alcohol and tobacco use, and promoting healthy diets. While prevention is essential, patients with a cancer diagnosis typically receive intensive and invasive treatments, including surgery, radiation therapy, chemotherapy, immunotherapy, and hormone therapy, which often have profound off-target effects on the body and brain that affect quality of life (QoL) through various mechanisms. Cancer and cancer treatments can cause physical discomfort, psychological distress, and a vast number of side effects, including pain, nausea and vomiting, fatigue, and sleep disturbances. Thus, strategies to decrease and alleviate such symptoms, and to promote and maintain general well-being and QoL for patients are critically needed.

Complementary and integrative medicine (CIM) treatments, including exercise, yoga/Tai Chi, and meditation, as an adjuvant to conventional oncology treatment may have beneficial impacts on psychological distress, anxiety, pain, fatigue, and sleep disturbances, leading to improved QoL in cancer patients. The mechanisms by which CIM interventions, particularly exercise, improve behavioral comorbidities in cancer patients are diverse, but likely involve modulatory effects on neuroimmune and neuroendocrine pathways associated with cancer and/or cancer treatment. Cancer-related fatigue (CRF), for instance, frequently co-occurs with elevated peripheral biomarkers of inflammation, including interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), which can feedback into the central nervous system, thereby altering mood and cognition. Prior studies also indicate that low heart rate variability (HRV), a physiological marker of autonomic dysregulation and catecholamine (ie, neuroendocrine) signaling, is associated with both CRF and greater plasma levels of IL-6 in cancer survivors. Importantly, yoga and exercise interventions in cancer patients have been shown to decrease circulating TNF-α levels, and may improve the autonomic nervous system (ANS) regulation. Furthermore, persistent low-grade inflammation promotes deleterious cancer processes, including angiogenesis, metastasis, chemoresistance, and survival, which occur in part through nuclear factor-κB (NF-κB)-mediated gene regulation of processes associated with apoptosis suppression, angiogenesis, tumor migration, metastasis, and resistance to chemotherapy and radiation treatment. In addition, key inflammatory cytokines, such as (IL-1 and TNF-α, activate NF-κB in cancer cells and may mediate cancer progression, and ANS imbalance is related to survival in a number of cancer populations.

Initiating or continuing to engage in traditional, positive health behaviors, such as maintaining adequate levels of PA, may enhance QoL, reduce fatigue, and improve depressive symptoms that are commonly associated with cancer diagnosis. Moreover, a recent review highlighted the cellular and molecular mechanisms by which physical exercise can mitigate cancer progression through direct effects on tumor intrinsic factors, including growth rate, metastasis, tumor metabolism, and immunogenicity, as well as regulation of tumor growth through systemic processes, and improved cancer treatment efficacy.

The Society of Integrative Oncology defines integrative oncology as “a patient-centered, evidence-informed field of cancer care that utilizes mind and body practices, natural products, and/or lifestyle modifications from different traditions alongside conventional cancer treatments. Integrative oncology aims to optimize health, QoL, and clinical outcomes across the cancer care continuum and to empower people to prevent cancer and become active participants before, during, and beyond cancer treatment.” The society recommends meditation, yoga, and relaxation with imagery to be routinely used for anxiety and mood disorders (evidence grade A), while stress management, yoga, massage, music therapy, energy conservation, and meditation are recommended for stress reduction, anxiety, depression, fatigue, and QoL (evidence grade B) of breast cancer patients. While the Society does not explicitly include PA in its guidelines, exercise programs are a common feature of integrative oncology practices globally.

In the present study, we sought to describe the characteristics of cancer patients who seek CIM in combination with conventional oncology treatments. Furthermore, by comparing patients according to PA and characterizing relationships between PA, QoL, inflammatory biomarkers, and autonomic balance, this study provides insights into factors associated with QoL in cancer patients. We hypothesized that patients who were more physically active postdiagnosis would report better QoL, less fatigue, better psychological outcomes, and be more likely to engage in healthful behaviors. Secondly, we hypothesized that more physically active patients would have lower levels of pro-inflammatory biomarkers and increased HRV, a measure of autonomic balance.
Methods

The present study is a cross-sectional analysis of a cohort of cancer patients at the time of enrollment in a supportive care clinic.

Setting

This study was conducted in a supportive care clinic called the InspireHealth Clinic, located in Vancouver, Canada. This is a physician-led, comprehensive cancer survivorship clinical care center providing integrative modalities, patient empowerment techniques, and lifestyle management approaches. The clinic staff is composed of family physicians and other professionals (including a registered holistic nutritionist, kinesiologist and exercise therapist, registered clinical counselor, integrated bodyworkers, and registered massage therapist). The InspireHealth foundations of health include sleep, rest and relaxation, exercise, healthy eating, avoidance of toxins, stress reduction, emotional connection, body-mind awareness, personal autonomy, joy and laughter, spiritual connection, hope, and will to live. Patients received their standard treatment at regional hospitals or branches of the British Columbia Cancer Agency.

Participants

Participants were patients enrolling in InspireHealth Clinic services. Inclusion criteria were to be at least 18 years; diagnosed with any type and stage of cancer; to be enrolling for the first time in the clinic; to have a performance status level ≤2 assessed by the Eastern Cooperative Oncology Group Performance Status31 to ensure that patients could adequately participate, as this tool describes the patient’s level of physical functioning and the ability to care for themselves. Participants had to be able and willing to participate in the study; able to provide informed consent; able to read and write in English; able and willing to answer the questionnaires and to provide blood samples. We analyzed data of participants who had PA data available.

Data Sources, Measurement, and Procedures

A study coordinator was responsible for patient recruitment and consenting, overseeing participants while completing the questionnaires, and managing participants’ files. When enrolling in the clinic, potential participants were told about the study, and if interested, the study coordinator contacted them by telephone or in person. They met with the study coordinator before their first physician visit, where they received comprehensive information about the study. All participants who met the eligibility criteria and agreed to participate signed the informed consent. Study numbers were assigned to participants for deidentification. The institutional review boards at Western Institutional Review Board (WIRB) approved this study with protocol number 20132240.

Participants completed all questionnaires during their clinic visit. The first part of the questionnaire captured self-reported sociodemographic characteristics, self-reported information about their cancer diagnosis, disease stage, treatment, family history of cancer, history of depression and anxiety, history of addiction, tobacco, and alcohol use. Participants also reported the use of medications and supplements (dose, purpose, and who prescribed it) and types of complementary and alternative medicine (CAM) therapies experienced. QoL was assessed with the Functional Assessment of Cancer Therapy–General (FACT-G) scale. This 29-item questionnaire is a validated and reliable tool that evaluates multiple dimensions of the QoL (physical, functional, emotional, and social well-being) during the previous week. Perceived level of social support was measured through the 19-item Medical Outcomes Study Social Support Survey (MOS-SSS), which quantifies overall support, as well as subscales assessing emotional/informational support, tangible support, positive interaction, and affection. We assessed anxiety and depression with the 14-item Hospital Anxiety and Depression Scale (HADS), which consists of 2 subscales ranging from 0 (no distress) to 21 (maximum distress). Based on suggested cutoffs, we classified participants as asymptomatic (≤7), borderline (8-10), or clinical cases (≥11). The FACT–Fatigue subscale was used to assess fatigue, which is a 13-item questionnaire previously validated in cancer patients. The items refer to the symptoms experienced in the past 7 days, and participants respond with 0 (not at all) to 4 (very much) how much they agree with the statements. Cancer-related symptoms were assessed with the Memorial Symptom Assessment Inventory–short form (MSAS-sf), which rates symptom distress associated with 26 physical symptoms, as well as the frequency of 4 psychological symptoms during the past week (eg, sadness, worry, irritability, nervousness). From the MSAS-sf assessment, subscales for physical and psychologic symptoms, a global distress index, and a total score were derived.

Patients reported their PA using a modified version of the Godin Leisure-Time Exercise Questionnaire (GLTEQ), which captured how many minutes per week they engaged in mild, moderate, and strenuous leisure PA. Patients reported their PA before and after the cancer diagnosis, and postdiagnosis PA was adopted to dichotomize the sample. Mild PA was described as activities requiring minimal effort, causing no perspiration (eg, easy walking, yoga, golf); moderate PA was defined as those not exhausting with light sweat (eg, fast walking, tennis, easy bicycling, easy swimming); and strenuous PA was described as those when the heart beats rapidly, causing sweat (eg, running, aerobic classes, vigorous swimming, or bicycling). The
level of PA (more or less active), according to weekly recommendations of 150 minutes of moderate or 75 minutes of vigorous PA, or an equivalent combination, was our key independent variable. Because evidence suggests that higher intensities of PA (eg, moderate to vigorous) may have stronger effects on cancer outcomes than total PA volume per se, total weekly time spent engaging in PA at each intensity was also used as an outcome measure in our exploratory biomarkers analyses (see below).

To assess inflammatory biomarkers, we collected a venous blood sample at the regional LifeLabs clinic at the location closest to each participant’s residence. A trained and certified phlebotomist drew 10 mL of nonfasting blood. Whole blood was centrifuged for plasma and frozen at –80°F. Samples were shipped on dry ice to the University of California, San Diego (UCSD) Clinical Research Biomarker Laboratory, and assayed via Meso Scale Discovery (MSD) Systems (Rockville, MD). The enzyme-linked immunosorbent assay (ELISA)-based platform allows for simultaneous assays of multiple analytes. We determined circulating levels of C-reactive protein (CRP), IL-6, TNF-α, vascular endothelial growth factor (VEGF), and IL1ra (IL-1 receptor antagonist) (CRP, IL-6, inter leukin 6; TNF-α, tumor necrosis factor-α; VEGF, vascular endothelial growth factor; IL1ra, interleukin-1 receptor antagonist).  

Intra- and inter-assay coefficients were <7% (Table 1).

As additional exploratory analyses, we investigated relationships between inflammation biomarkers and QoL with different PA intensities through Spearman’s correlations. Finally, we conducted a hierarchical multivariable regression analysis with QoL (total score) as the dependent variable. All tests were 2-tailed. The results were considered significant at the P < .05 level. We performed all analyses using SPSS (version 26.0) software package (IBM, Armonk, NY).

### Statistical Analysis

Distribution of variables was checked using the Shapiro-Wilk’s normality test. We calculated means and standard deviations for continuous variables, and absolute values and frequencies for categorical ones. Group comparisons (more active vs less active) were conducted using independent t tests or Mann-Whitney U and χ² tests. We conducted a factorial analysis of biomarkers related to inflammation (CRP, IL-6, TNF-α, VEGF, IL1ra), to mitigate multicollinearity and reduce dimensionality, thereby creating an inflammatory index whereby higher values indicate greater circulating biomarker concentrations.

### Results

#### Sociodemographic and Health-Related Characteristics

Patients (N = 162) were enrolled from December 2014 until April 2016 (Table 2). From these, 118 participants (69.5% female; aged 56.6 ± 11.3 years) with complete PA...
data composed our sample. Based on the American Cancer Society (ACS)’s PA guidelines, 53 patients (44.9%) met the criteria for sufficient PA, whereas 65 patients (55.1%) did not. Table 3 contains the clinical characteristics of the sample, stratified by activity level. Breast cancer was the most prevalent primary cancer diagnosis, affecting 33.1% of participants, followed by prostate cancer (10.2%), ovarian cancer, and lymphoma (9.3%). Regarding the stage of cancer, patients were roughly equally distributed across stages 1 to 4. Importantly, cancer stages did not differ between the less and more active groups ($\chi^2 = 3.95, P = .41$). The most common cancer treatments before enrolling in the InspireHealth clinic were classified as “other” (54.4%), followed by onetime surgery (21.1%), and >1 chemotherapy treatment (11.4%). Patients provided a qualitative description of which “other” therapies they had undergone, and no group differences in the prevalence of “other” therapeutic modalities were observed ($\chi^2 = 12.18, P = .431$). Within the “other” therapies, patients identified: (1) planned, near-term cancer treatment (less vs more active: 28.6% vs 22.2%); received (2) steroid treatment (2.9% vs none); (3) combination of surgery and radiotherapy (14.3% vs 11.1%); (4) surgery and hormone therapy (2.9% vs none); (5) surgery and chemotherapy (20% vs 7.4%); (6) surgery and

### Table 2. Self-Reported Sociodemographic Characteristics According to the Amount of Physical Activity (Reported as Means ± SDs or Absolute and Relative [%] Values).

| Characteristic                  | Total       | Less Active | More Active | Test Statistics | $P$  | Effect Sizes |
|-------------------------------|-------------|-------------|-------------|-----------------|-----|--------------|
| Age (years)                   | 56.6 ± 11.3 | 55.5 ± 11.0 | 58.0 ± 11.6 | 1475            | .180| −0.12b       |
| Sex                           | 118         | 65          | 53          |                 |     |              |
| Male                          | 36 (30.5)   | 15 (23.1)   | 21 (39.6)   |                 |     |              |
| Female                        | 82 (69.5)   | 50 (76.9)   | 32 (60.4)   |                 |     |              |
| Ethnicity                     | 118         | 65          | 53          |                 |     |              |
| Asian/Pacific Islander        | 18 (15.3)   | 11 (16.9)   | 7 (13.2)    |                 |     |              |
| African/Black North American  | 1 (0.8)     | 1 (1.5)     | —           |                 |     |              |
| Caucasian                     | 87 (73.7)   | 44 (50.6)   | 43 (81.1)   |                 |     |              |
| East Indian                   | 2 (1.7)     | 1 (1.5)     | 1 (1.9)     |                 |     |              |
| Hispanic/Latino               | 2 (1.7)     | 2 (3.1)     | —           |                 |     |              |
| Native American/Native        | 1 (0.8)     | 1 (1.5)     | —           |                 |     |              |
| Alaskan                       | 7 (5.9)     | 2 (3.8)     | 2 (3.8)     |                 |     |              |
| Education level               | 118         | 65          | 53          |                 |     |              |
| Some high school              | 1 (0.8)     | 1 (1.5)     | —           |                 |     |              |
| High school graduate          | 5 (4.2)     | 2 (3.1)     | 3 (5.7)     |                 |     |              |
| Some college                  | 23 (19.5)   | 13 (20)     | 10 (18.9)   |                 |     |              |
| College diploma               | 11 (9.3)    | 4 (6.2)     | 7 (13.2)    |                 |     |              |
| 2-year college graduate       | 9 (7.6)     | 3 (4.6)     | 6 (11.3)    |                 |     |              |
| 4-year college graduate       | 19 (16.1)   | 11 (16.9)   | 8 (15.1)    |                 |     |              |
| Attended university           | 4 (3.4)     | 3 (4.6)     | 1 (1.9)     |                 |     |              |
| University degree             | 11 (9.3)    | 8 (12.3)    | 3 (5.7)     |                 |     |              |
| Some graduate school          | 1 (0.8)     | 1 (1.5)     | —           |                 |     |              |
| Postgraduate degree           | 33 (28)     | 18 (27.7)   | 15 (28.3)   |                 |     |              |
| Partner status                | 117         | 64          | 53          |                 |     |              |
| Single, never married         | 20 (17.1)   | 10 (15.6)   | 10 (18.9)   |                 |     |              |
| Separated/divorced            | 21 (17.9)   | 10 (15.6)   | 11 (20.8)   |                 |     |              |
| Widowed                       | 2 (1.7)     | 2 (3.1)     | —           |                 |     |              |
| Living with a partner         | 12 (10.3)   | 10 (15.6)   | 2 (3.8)     |                 |     |              |
| Married living with a spouse  | 62 (53)     | 32 (50)     | 30 (56.6)   |                 |     |              |
| Children                      | 116         | 64          | 52          |                 |     |              |
| No                            | 47 (40.5)   | 23 (35.9)   | 24 (46.2)   |                 |     |              |
| Yes                           | 69 (59.5)   | 41 (64.1)   | 28 (53.8)   |                 |     |              |

*aTest statistics are reported as $U$ for continuous variables and as $\chi^2$ for categorical variables.  
*bEffect size reported as $r$.  
*cEffect sizes reported as Phi.  
*dEffect sizes reported as Cramer’s $V$.  

---
Table 3. Self-Reported Health-Related Characteristics of the Total Sample and by the Amount of Physical Activity (Reported as Absolute and Relative [%] Values).

|                          | Total n | Less Active n | More Active n | χ²     | P     | Cramér’s V |
|--------------------------|---------|---------------|---------------|--------|-------|------------|
| Primary cancer diagnosis |         |               |               |        |       |            |
| Bladder                  | 118     | 65            | 53            | 41.79  | .014  | 0.54       |
| Brain                    | 4 (3.4) | 2 (3.1)       | 2 (3.8)       |        |       |            |
| Breast                   | 39 (33.1)| 25 (38.5)    | 14 (26.4)     |        |       |            |
| Cervical                 | 1 (0.8) | 1 (1.5)       |               |        |       |            |
| Colon                    | 8 (6.8) | 6 (9.2)       | 2 (3.8)       |        |       |            |
| Colorectal               | 2 (1.7) | 1 (1.5)       | 1 (1.9)       |        |       |            |
| Endometrial              | 4 (3.4) | 1 (1.5)       | 3 (5.7)       |        |       |            |
| Epithelioid              | 1 (0.8) |               | 1 (1.9)       |        |       |            |
| Esophageal               | 2 (1.7) | 1 (1.5)       | 1 (1.9)       |        |       |            |
| Gastrointestinal         | 1 (0.8) | 1 (1.5)       |               |        |       |            |
| Laryngeal                | 1 (0.8) |               | 1 (1.9)       |        |       |            |
| Leiomyosarcoma           | 1 (0.8) | 1 (1.5)       |               |        |       |            |
| Leukemia                 | 2 (1.7) | 2 (3.1)       |               |        |       |            |
| Lung                     | 3 (2.5) | 2 (3.1)       | 1 (1.9)       |        |       |            |
| Lymphoma                 | 11 (9.3)| 4 (6.2)       | 7 (13.2)      |        |       |            |
| Melanoma                 | 1 (0.8) | 1 (1.5)       |               |        |       |            |
| Multiple myelomas        | 1 (0.8) | 1 (1.5)       |               |        |       |            |
| Ovarian                  | 11 (9.3)| 9 (13.8)      | 2 (3.8)       |        |       |            |
| Pheochromocytoma         | 1 (0.8) | 1 (1.5)       |               |        |       |            |
| Prostate                 | 12 (10.2)| 1 (1.5)     | 11 (20.8)     |        |       |            |
| Rectal                   | 2 (1.7) | 2 (3.1)       |               |        |       |            |
| Skin                     | 1 (0.8) |               | 1 (1.9)       |        |       |            |
| Thyroid                  | 2 (1.7) | 1 (1.5)       | 1 (1.9)       |        |       |            |
| Tongue                   | 1 (0.8) |               | 1 (1.9)       |        |       |            |
| Uterine                  | 5 (4.2) | 2 (3.1)       | 3 (5.7)       |        |       |            |
| Cancer stage             |         |               |               |        |       |            |
| Stage 1                  | 18 (19.4)| 10 (18.2)   | 8 (21.1)      |        |       |            |
| Stage 2                  | 20 (21.5)| 11 (20)      | 9 (23.7)      |        |       |            |
| Stage 3                  | 23 (24.7)| 17 (20.9)   | 6 (15.8)      |        |       |            |
| Stage 4                  | 24 (25.8)| 14 (25.5)   | 10 (26.3)     |        |       |            |
| Unknown                  | 8 (8.6) | 3 (5.5)       | 5 (13.2)      |        |       |            |
| Cancer treatment before admission |         |               |               |        |       |            |
| Chemotherapy (1 ×)       | 5 (4.4) | 2 (3.1)       | 3 (6)         |        |       |            |
| Chemotherapy (>1)        | 13 (11.4)| 9 (14.1)     | 4 (8)         |        |       |            |
| Surgery (1 ×)            | 24 (21.1)| 12 (18.8)   | 12 (24)       |        |       |            |
| Surgery (>1)             | 3 (2.6) | 2 (3.1)       | 1 (2)         |        |       |            |
| Radiation (1 ×)          | 3 (2.6) | 1 (1.6)       | 2 (4)         |        |       |            |
| Radiation (>1)           | 4 (3.5) | 3 (4.7)       | 1 (2)         |        |       |            |
| Other                    | 62 (54.4)| 35 (54.7)    | 27 (54)       |        |       |            |
| Family cancer history    |         |               |               |        |       |            |
| No history               | 21 (17.9)| 9 (13.8)     | 12 (23.1)     |        |       |            |
| Close family member      | 19 (16.2)| 11 (16.9)    | 8 (15.4)      |        |       |            |
| Parent with cancer       | 23 (19.7)| 10 (15.4)    | 13 (25)       |        |       |            |
| Multiple family members  | 54 (46.2)| 35 (54.8)    | 19 (36.5)     |        |       |            |
| Self-reported history of depression |         |               |               |        |       |            |
| Much less than the average person | 35 (29.7)| 20 (30.8)  | 15 (42.9)     |        |       |            |
| Less than average        | 21 (17.8)| 7 (10.8)     | 14 (26.4)     |        |       |            |
| Like average person      | 32 (27.1)| 16 (24.6)    | 16 (30.2)     |        |       |            |
| More than average        | 27 (22.9)| 19 (29.2)    | 8 (29.6)      |        |       |            |
| Much more than the average person | 3 (2.5) | 3 (4.6)       |               |        |       |            |
| Self-reported history of anxiety |         |               |               |        |       |            |
| Much less than the average person | 29 (24.6)| 15 (23.1)    | 14 (26.4)     |        |       |            |
| Less than average        | 16 (13.6)| 10 (15.4)    | 6 (11.3)      |        |       |            |
| Like average person      | 31 (26.3)| 16 (24.6)    | 15 (28.3)     |        |       |            |
| More than average        | 37 (31.4)| 20 (30.8)    | 17 (32.1)     |        |       |            |
| Much more than the average person | 5 (4.2) | 4 (6.2)       | 1 (1.9)       |        |       |            |
cystoscopy (none vs 3.7%); (7) combination of surgery, radiotherapy, and chemotherapy (11.4% vs 14.8%); (8) combination of surgery, radiotherapy, and hormone therapy (none vs 3.7%); (9) chemotherapy and radiotherapy (2.9% vs 7.4%); (10) chemotherapy and a transplant (5.7% vs none); (11) chemotherapy and Gerson therapy (none vs 3.7%); (12) radiation and hormone therapy (none vs 3.7%); and (13) no therapy or information available (11.4% vs 22.2%; data not shown in tables). Participants in the more active group reported a significantly lower incidence of history of depression than the less active group ($\chi^2 = 10.64, P = .031$). Many participants (31.4%) reported having a history of greater anxiety than the “average person,” but the prevalence did not differ between groups ($\chi^2 = 2.02, P = .731$).

Health-related behaviors of the participants are shown in Table 4. Most patients (89.7%) did not have a history of addiction and never smoked (94.9%), though all current and former smokers were contained within the less active group ($\chi^2 = 7.41, P = .025$). Occasional alcohol consumption (once a week or less) was a prevalent behavior (49.2%) among all patients. Self-reported engagement in leisure PA was, on average, 283 min/week, and most time was spent engaging in activities of mild (135 min/week) to moderate (114 min/week) intensity. In general, participants had an extensive regimen of medications. Analgesic and chemotherapy drugs were the most prevalent (15.6% and 14.5%, respectively), and physicians prescribed 56.7% of the medications. Most participants (77.4%) reported the use of some supplements. Less active patients used significantly more supplements than the more active patients (66.9% vs 33.1%, $\chi^2 = 39.74, P < .001$), and vitamin supplements were prevalent (37.2%). Naturopathic physicians prescribed more supplements (12.2%) than other physicians (8.1%). Participants had a previous engagement with complementary or alternative therapies, mostly massage (75.2%) and yoga (66.1%) and acupuncture (59.6%).

### Physical Activity and Psychosocial Characteristics

Patients who were more physically active reported better QoL ($U = 1341, P = .039$), and greater physical ($U = 1265.5, P = .013$) and functional ($U = 1306.5, P = .024$) well-being. The prevalence of depressive symptoms was significantly lower among more active patients ($\chi^2 = 6.13, P = .047$). More active participants also reported less fatigue ($U = 1268, P = .014$), fewer physical symptoms related to cancer ($U = 2.338, P = .021$), and less generalized distress ($U = 2.339, P = .021$) compared with less active participants. Social, familial, or emotional well-being subscales did not differ between PA groups, nor did perceived social support or anxiety prevalence (Table 5).

In addition to classifying patients into less and more active groups based on ACS guidelines, we also assessed the amount of PA for all participants within each intensity level (eg, weekly minutes of mild, moderate, or vigorous activity) as a continuous measure. When exploring the relationship between QoL and PA, we found positive correlations for total time ($r_s = 0.227, P = .014$) and moderate-intensity PA ($r_s = 0.291, P = .001$) (Table 6). A hierarchical multivariable linear regression model was implemented to investigate the correlates of total QoL score (Table 7). The overall model explained 71.1% of the variability in our dependent variable, with age ($\beta = 0.22; P = .001$), fatigue ($\beta = -0.43; P < .001$), anxiety ($\beta = -0.14; P = .048$) and social support ($\beta = 0.38; P = .001$) as significant correlates of total QoL.

### Biomarkers

Heart rate was significantly lower in more physically active patients during the acclimation phase ($t = 2.085, P = .039$) and the resting period ($t = 2.120, P = .036$) of the HRV assessment. Across all other cardiopulmonary measures of health, differences between groups were not statistically significant.

After examining PA levels (more versus less active, according to ACS guidelines), we decided to explore relationships of PA intensities and inflammation, as prior studies have suggested that high intensities of exercise might have a differential impact on inflammation. Biomarkers related to inflammation and autonomic balance are reported in Tables 6 and 8. All 5 inflammatory biomarkers were entered into a factor analysis to reduce the number of analyses, which resulted in a single stable component (Eigenvalue = 2.075) that explained 41.9% of the variance and was used in subsequent analyses. The individual factor component scores were then used as a unitary inflammatory index for each patient. Vigorous PA was inversely associated with the inflammatory index ($r_s = -0.215, P = .022$). Heart rate was significantly lower in more physically active patients during the acclimation phase ($t = 2.085, P = .039$) and the resting period ($t = 2.120, P = .036$) of the HRV assessment. Across all other measures of health, differences between groups were not statistically significant.

### Discussion

The patients in this study were similar to other studies describing characteristics of cancer patients seeking CIM: predominantly middle-aged, white, and a large proportion affected by breast cancer. We identified different stages of cancer in our sample, demonstrating that regardless of disease stage, integrative care seems attractive to cancer patients. In Germany, a survey found that 75% of patients with advanced breast cancer (including patients with adjuvant cancer, local recurrence, and primary metastasis) were interested in complementary
|                                | Total     | Less Active | Test Statistics\(^a\) | P       | Effect Sizes |
|--------------------------------|-----------|-------------|------------------------|---------|--------------|
| History of addiction          | 117       | 65          | 2.67                   | .102    | 0.15\(^b\)   |
| No                             | 105 (89.7)| 61 (93.8)   |                        |         |              |
| Yes                            | 12 (10.3) | 4 (6.2)     |                        |         |              |
| Tobacco use                    | 118       | 65          | 7.41                   | .025    | 0.20\(^c\)   |
| Never                          | 112 (94.9)| 59 (90.8)   |                        |         |              |
| Occasionally (1 ×/week or less)| 1 (0.8)  | 1 (1.5)     |                        |         |              |
| Every day or almost every day  | 5 (4.2)   | 5 (7.7)     |                        |         |              |
| Alcohol use                    | 117       | 64          | 5.14                   | .076    | 0.21\(^c\)   |
| Never                          | 42 (35.6) | 25 (39.1)   |                        |         |              |
| Occasionally (1 ×/week or less)| 58 (49.2)| 34 (53.1)   |                        |         |              |
| Every day or almost every day  | 17 (14.4)| 5 (7.8)     |                        |         |              |
| Physical activity before diagnosis (min/week) (GLTEQ) | 118 | 65 | 1379 | .055 | −0.17\(^d\) |
| Vigorous                       | 110.97 ± 154.17 | 94.65 ± 18.40 | 130.99 ± 21.99 | 1379 | .055 | −0.17\(^d\) |
| Moderate                       | 167.54 ± 189.17 | 171.94 ± 23.77 | 162.15 ± 25.79 | 1688 | .854 | −0.01\(^d\) |
| Mild                           | 161.80 ± 216.70 | 166.15 ± 31.92 | 156.46 ± 21.31 | 1513 | .255 | −0.10\(^d\) |
| Total                          | 440.31 ± 400.25 | 432.74 ± 58.30 | 449.60 ± 40.81 | 1386 | .069 | −0.16\(^d\) |
| Physical activity after diagnosis (min/week) (GLTEQ) | 118 | 65 | 929 | <.001 | −0.50\(^d\) |
| Vigorous                       | 33.67 ± 70.25 | 3.92 ± 17.24  | 70.14 ± 90.99  | 929 | <.001 | −0.50\(^d\) |
| Moderate                       | 114.08 ± 130.60 | 29.36 ± 47.01 | 217.97 ± 125.20 | 191 | <.001 | −0.78\(^d\) |
| Mild                           | 135.97 ± 160.69 | 131.19 ± 177.49 | 141.84 ± 138.79 | 1504 | .234 | −0.10\(^d\) |
| Total                          | 283.71 ± 232.19 | 164.47 ± 174.34 | 429.95 ± 210.54 | 381 | <.001 | −0.66\(^d\) |
| Reported use of medications    | 118       | 65          | 42.91                  | .076    | 0.34\(^c\)   |
| Acid reducer                   | 17 (5.9)  | 10 (5.5)    | 7 (6.5)                |         |              |
| Antidiarrheal                  | 2 (0.7)   | 1 (0.6)     | 1 (0.9)                |         |              |
| Antidiarrheal                  | 14 (4.8)  | 9 (5.0)     | 5 (4.6)                |         |              |
| Antihistamine                  | 6 (2.1)   | 4 (2.2)     | 2 (1.9)                |         |              |
| Antihypertensive               | 23 (8.0)  | 14 (7.7)    | 9 (8.3)                |         |              |
| Antimigraine                   | 1 (0.3)   | 1 (0.6)     | —                      |         |              |
| Antiviral                      | 4 (1.4)   | 2 (1.1)     | 2 (1.9)                |         |              |
| Benign prostatic hypertensive  | 3 (1.0)   | —           | 3 (2.8)                |         |              |
| Bile agent acid                | 1 (0.3)   | 1 (0.6)     | —                      |         |              |

(continued)
Table 4. (continued)

|                       | Total | n   | Less Active | n   | More Active | n   | Test Statisticsa | P    | Effect Sizes |
|-----------------------|-------|-----|-------------|-----|-------------|-----|------------------|------|--------------|
| Bronchodilator        | 5 (1.7) | 4 (2.2) | 1 (0.9)    |     |             |     |                  |      |              |
| Chemotherapy          | 42 (14.5) | 28 (15.5) | 14 (13.0) |     |             |     |                  |      |              |
| Anal fissure treatment| 1 (0.3) | — | 1 (0.9)    |     |             |     |                  |      |              |
| Cholesterol reducer   | 8 (2.8) | 6 (3.3) | 2 (1.9)    |     |             |     |                  |      |              |
| Hematopoietic agent   | 1 (0.3) | 1 (0.6) | — |     |             |     |                  |      |              |
| Hormone therapy       | 25 (8.7) | 14 (7.7) | 11 (10.2) |     |             |     |                  |      |              |
| Laxative              | 2 (0.7) | 2 (1.1) | — |     |             |     |                  |      |              |
| Mucolytic agent       | 1 (0.3) | — | 1 (0.9)    |     |             |     |                  |      |              |
| Muscarinic antagonist  | 2 (0.7) | 1 (0.6) | 1 (0.9)    |     |             |     |                  |      |              |
| Muscle relaxant       | 2 (0.7) | 1 (0.6) | 1 (0.9)    |     |             |     |                  |      |              |
| Sleeping aid/calming  | 23 (8.0) | 16 (8.8) | 7 (6.5)    |     |             |     |                  |      |              |
| Steroid               | 17 (5.9) | 10 (5.5) | 7 (6.5)    |     |             |     |                  |      |              |
| Stimulant             | 2 (0.7) | 1 (0.6) | 1 (0.9)    |     |             |     |                  |      |              |
| Analgesic             | 45 (15.6) | 26 (14.4) | 19 (17.6) |     |             |     |                  |      |              |
| Triptan               | 2 (0.7) | 2 (1.1) | — |     |             |     |                  |      |              |
| Ulcerative colitis treatment | 1 (0.3) | — | 1 (0.9)    |     |             |     |                  |      |              |
| Xanthine oxidase inhibitor | 1 (0.3) | — | 1 (0.9)    |     |             |     |                  |      |              |
| Antidiabetic          | 4 (1.4) | 4 (2.2) | — |     |             |     |                  |      |              |
| Antipsychotic         | 2 (0.7) | 2 (1.1) | — |     |             |     |                  |      |              |
| Antibiotics           | 4 (1.4) | — | 4 (3.7)    |     |             |     |                  |      |              |
| Anticoagulant         | 1 (0.3) | — | 1 (0.9)    |     |             |     |                  |      |              |
| Anticonvulsant        | 3 (1.0) | 2 (1.1) | 1 (0.9)    |     |             |     |                  |      |              |
| Antidepressant        | 24 (8.3) | 19 (10.5) | 5 (4.6)    |     |             |     |                  |      |              |
| Total                 | 289 (100) | 181 (62.6) | 108 (37.4) |     |             |     |                  |      |              |
| Who prescribed the drugs | 118 | 65 | 53 | 14.44 | .001 | 0.22c | | | |
| Physician             | 164 (56.7) | 88 (48.6) | 76 (70.4) |     |             |     |                  |      |              |
| Self                  | 4 (1.4) | 2 (1.1) | 2 (1.9)    |     |             |     |                  |      |              |
| Missing information   | 121 (41.9) | 91 (50.3) | 30 (24.8) |     |             |     |                  |      |              |
| Reported use of supplements | 118 | 65 | 53 | 39.74 | <.001 | 0.29c | | | |
| Amino acids           | 9 (2.3) | 5 (1.9) | 4 (3.1)    |     |             |     |                  |      |              |
| Fatty acids           | 23 (5.9) | 14 (5.3) | 9 (6.9)    |     |             |     |                  |      |              |
| Homeopathy            | 1 (0.3) | — | 1 (0.8)    |     |             |     |                  |      |              |

(continued)
| Types of CAM therapies                        | Total       | n   | Less Active | n     | More Active | n     | Test Statistics<sup>a</sup> | P     | Effect Sizes<sup>b</sup> |
|----------------------------------------------|-------------|-----|-------------|-------|------------|-------|-----------------------------|-------|--------------------------|
| Acupuncture                                  | 65 (59.6)   | 109 | 38 (63.3)   | 60    | 27 (55.1)  | 49    | 0.759                       | 0.384 | −0.08<sup>c</sup>        |
| Muscle relaxation exercises                  | 36 (33)     | 109 | 19 (31.7)   | 60    | 17 (34.7)  | 49    | 0.112                       | 0.738 | 0.03<sup>b</sup>         |
| Yoga                                        | 72 (66.1)   | 109 | 39 (65)     | 60    | 33 (67.3)  | 49    | 0.066                       | 0.797 | 0.02<sup>b</sup>         |
| Visualization exercises                      | 43 (39.4)   | 109 | 22 (36.7)   | 60    | 21 (42.9)  | 49    | 0.433                       | 0.511 | 0.06<sup>b</sup>         |
| Stress reduction exercises                   | 30 (27.5)   | 109 | 16 (26.7)   | 60    | 14 (28.6)  | 49    | 0.049                       | 0.825 | 0.02<sup>b</sup>         |
| Massage                                      | 82 (75.2)   | 109 | 48 (80)     | 60    | 34 (69.4)  | 49    | 1.630                       | 0.202 | 0.12<sup>b</sup>         |
| Hypnosis                                     | 22 (20.2)   | 109 | 13 (21.7)   | 60    | 9 (18.4)   | 49    | 0.182                       | 0.669 | 0.04<sup>b</sup>         |
| Naturopath medicine                          | 45 (41.3)   | 109 | 24 (40)     | 60    | 21 (42.9)  | 49    | 0.091                       | 0.763 | 0.02<sup>b</sup>         |
| Dietary vitamin therapies                    | 42 (38.5)   | 109 | 24 (40)     | 60    | 18 (36.7)  | 49    | 0.121                       | 0.727 | 0.03<sup>b</sup>         |
| Other                                        | 31 (28.4)   | 103 | 22 (36.7)   | 56    | 9 (18.4)   | 47    | 4.438                       | 0.035 | −0.20<sup>b</sup>        |

Abbreviations: GLTEQ, Godin Leisure-Time Exercise Questionnaire; CAM, complementary and alternative medicine.

<sup>a</sup>Test statistics are reported as U for continuous variables and as χ² for categorical variables.

<sup>b</sup>Effect sizes reported as Phi.

<sup>c</sup>Effect sizes reported as Cramér’s V.
A more extensive German study, including 3411 patients from 339 centers, found that 46.4% of breast cancer patients (tumor stages varied from 1 to 4) were interested in integrative medicine. In California, 95% of 166 advanced gastric nonsurgical patients were involved in at least one type of integrative care approach while receiving care in a hospital. Moreover, a survey of hospitalized Canadian cancer patients found that 86% reported to have

| Table 5. Self-Reported Psychosocial and Physical Characteristics of the Total Sample and by the Amount of Physical Activity (Reported as Means ± SDs or Absolute and Relative [%] Values). |
|------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                  | Total (n = 118) | Less Active (n = 65) | More Active (n = 53) | Test Statistics | P | Effect Sizes |
| Quality of life (FACT-G) |                  |                  |                  |                 |    |              |
| Physical well-being | 21.56 ± 5.55    | 20.62 ± 5.65 | 22.72 ± 5.25 | 1265.5         | .013 | −0.22b         |
| Social and family well-being | 20.31 ± 5.62    | 20.17 ± 6.22 | 20.49 ± 4.83 | 1615           | .559 | −0.05b         |
| Emotional well-being | 16.08 ± 4.90    | 15.48 ± 4.58 | 16.81 ± 5.20 | 1410.5         | .091 | −0.15b         |
| Functional well-being | 18.25 ± 5.66    | 17.17 ± 5.72 | 19.58 ± 5.33 | 1306.5         | .024 | −0.20b         |
| Total score        | 76.20 ± 15.47   | 74.33 ± 16.43 | 79.60 ± 13.59 | 1341           | .039 | −0.19b         |
| Social support (MOS-SSS) |                |                  |                  |                 |    |              |
| Emotional/informational support | 72.64 ± 24.30 | 69.47 ± 25.70 | 76.53 ± 22.05 | 1444           | .130 | −0.13b         |
| Tangible support   | 72.56 ± 31.97   | 70.86 ± 34.23 | 74.64 ± 29.14 | 1674           | .788 | −0.02b         |
| Affectionate support | 78.96 ± 29.72   | 77.56 ± 31.79 | 80.66 ± 27.13 | 1650           | .671 | −0.03b         |
| Positive social interaction support | 77.40 ± 25.95 | 75.00 ± 27.40 | 80.38 ± 23.96 | 1560           | .357 | −0.08b         |
| Overall support    | 74.47 ± 23.79   | 71.98 ± 25.54 | 77.50 ± 21.27 | 1504           | .237 | −0.10b         |
| Anxiety (HADS)     |                  |                  |                  |                 |    |              |
| Asymptomatic       | 72 (61)         | 39 (60)         | 33 (62.3)       |                 |    |              |
| Borderline         | 22 (18.6)       | 13 (20)         | 9 (17)          |                 |    |              |
| Clinical case      | 24 (20.3)       | 13 (20)         | 11 (20.8)       |                 |    |              |
| Depression (HADS)  |                  |                  |                  |                 |    |              |
| Asymptomatic       | 101 (85.6)      | 51 (78.5)       | 50 (94.3)       |                 |    |              |
| Borderline         | 8 (6.8)         | 7 (10.8)        | 1 (1.9)         |                 |    |              |
| Clinical case      | 9 (7.6)         | 7 (10.8)        | 2 (3.8)         |                 |    |              |
| Fatigue (FACT)     | 17.49 ± 11.38   | 20.06 ± 12.10  | 14.33 ± 9.63   | 1268           | .014 | −0.22b         |
| Symptoms associated with cancer (MSAS-sf) |            |                  |                  |                 |    |              |
| Physical symptoms  | 1.32 ± 0.43     | 1.40 ± 0.44     | 1.22 ± 0.39     | 2.338           | .021 | −0.21b         |
| Psychological symptoms | 1.47 ± 0.59     | 1.52 ± 0.61     | 1.40 ± 0.56     | 1.049           | .296 | −0.22b         |
| Global distress index | 1.40 ± 0.45     | 1.49 ± 0.47     | 1.30 ± 0.41     | 2.339           | .021 | −0.09b         |
| Total score        | 1.32 ± 0.37     | 1.39 ± 0.39     | 1.25 ± 0.32     | 2.061           | .042 | −0.16b         |

Abbreviations: FACT-G, Functional Assessment of Cancer Therapy–General scale; MOS-SSS, Medical Outcomes Study Social Support Survey; HADS, Hospital Anxiety and Depression Scale; FACT, Functional Assessment of Cancer Therapy–Fatigue subscale; MSAS-sf, Memorial Symptom Assessment Inventory–Short-form.

*Effect size reported as r.  
*Effect sizes reported as Cramér’s V.

Table 6. Associations of the Inflammatory Biomarker Index and Quality of Life With Different Physical Activity Intensities (Light, Moderate, Vigorous, and Total Time of Physical Activity).

|                  | Total Time | Light | Moderate | Vigorous |
|------------------|------------|-------|----------|----------|
|                  | rs | Pe   | rs | P | rs | P | rs | P |
| Inflammatory index | −0.150 | .115 | −0.029 | .763 | −0.171 | .071 | −0.215 | .022 |
| QoL (FACT-G)     | 0.227 | .014 | 0.028 | .761 | 0.291 | .001 | 0.092 | .323 |

Abbreviations: QoL, quality of life; FACT-G, Functional Assessment of Cancer Therapy–General scale.
received complementary care in the past month, and 91% in the past year; their reasons for its use included a desire to “feel good,” to relieve symptoms and side effects, and mostly to improve their overall QoL.51 Although rates of CIM utilization vary across settings and populations, a large proportion of cancer patients seek complementary therapies and express interest in integrative care for their condition.

In assessing the health-related behaviors of our study population, smoking was rare (5%), and among the more physically active patients, none were smokers. Our smoking rates were much lower than a Canadian case-control study that investigated PA in cancer patients, with a 14% rate of current smokers and 29.1% nonsmokers,53 potentially indicating that CIM-seeking patients engage in fewer harmful health behaviors than cancer patients as a whole. In support of that hypothesis, we also found that alcohol consumption was particularly infrequent in our sample. Regarding PA, in general, participants engaged primarily in moderate- to mild-intensity activity after their cancer diagnosis. For a reference, both the ACS guidelines for cancer prevention38 and the Canadian guidelines for exercise during and post–cancer treatment,54 recommend at least 150 minutes of moderate PA per week for cancer prevention and improvement of QoL for those fighting cancer. Cancer patients experience barriers to exercise resulting from treatment-related side effects, lack of time, and fatigue.55 Despite these limitations, cancer patients should be encouraged to exercise in moderate to vigorous intensities when possible to benefit from the effectiveness of regular exercise to increase the QoL,23,56 muscular and aerobic fitness,54 to reduce fatigue, depression, anxiety, and sleep disturbances.56

Our sample reported taking a variety of medications, with chemotherapies and analgesics being the most prevalent. Also, 77.4% of the participants reported using some supplement, with vitamins, including single-type or multicomplex of vitamins, being most frequently used.

### Table 7. Hierarchical Multivariable Linear Regression Model Predicting the Quality of Life in Cancer Patients (n = 86).

| Step | $R^2$ | Adjusted $R^2$ | $\Delta R^2$ | Unstandardized $\beta$ (95% CI) | SE B | Standard Coefficients $\beta$ | VIF | $P$ |
|------|-------|----------------|-------------|----------------------------------|-----|-----------------------------|-----|-----|
| 1    | 0.131 | 0.110          |             | Constant                         | 50.98 (30.46 to 71.50) | 10.31 |    | <.001 |
|      |       |                |             | Age                              | 0.48 (0.20 to 0.75) | 0.14 | 0.36 | 1.005 | .001 |
|      |       |                |             | Sex                              | −1.35 (−8.52 to 5.82) | 3.61 | −0.04 | 1.005 | .709 |
| 2    | 0.496 | 0.388          |             | Constant                         | 72.58 (56.03 to 89.12) | 8.32 |    | <.001 |
|      |       |                |             | Age                              | 0.30 (0.09 to 0.51) | 0.10 | 0.22 | 1.055 | .006 |
|      |       |                |             | Sex                              | 1.52 (−4.02 to 7.06) | 2.78 | 0.04 | 1.057 | .586 |
|      |       |                |             | Cancer stage                     | 0.002 (0.000 to 0.004) | 0.001 | 0.13 | 1.076 | .111 |
|      |       |                |             | Fatigue level                    | −0.90 (−1.12 to −0.68) | 0.11 | −0.65 | 1.102 | .000 |
| 3    | 0.714 | 0.218          |             | Constant                         | 64.26 (47.90 to 80.63) | 8.22 |    | <.001 |
|      |       |                |             | Age                              | 0.30 (0.13 to 0.47) | 0.08 | 0.22 | 1.215 | .001 |
|      |       |                |             | Sex                              | −0.42 (−4.65 to 3.81) | 2.12 | −0.01 | 1.090 | .843 |
|      |       |                |             | Cancer stage                     | 0.001 (0.000 to 0.003) | 0.001 | 0.09 | 1.163 | .130 |
|      |       |                |             | Fatigue level                    | −0.59 (−0.78 to −0.40) | 0.09 | −0.43 | 1.417 | <.001 |
|      |       |                |             | Depression                       | −5.77 (−11.71 to 0.16) | 2.98 | −0.13 | 1.490 | .056 |
|      |       |                |             | Anxiety                          | −2.92 (−5.83 to −0.02) | 1.45 | −0.14 | 1.599 | .049 |
|      |       |                |             | Social support                   | 0.23 (0.16 to 0.32) | 0.04 | 0.38 | 1.204 | <.001 |
| 4    | 0.711 | <0.001         |             | Constant                         | 63.85 (47.11 to 80.58) | 8.40 |    | <.001 |
|      |       |                |             | Age                              | 0.30 (0.13 to 0.47) | 0.08 | 0.22 | 1.216 | .001 |
|      |       |                |             | Sex                              | −0.31 (−4.65 to 4.03) | 2.18 | −0.09 | 1.130 | .888 |
|      |       |                |             | Cancer stage                     | 0.001 (0.000 to 0.003) | 0.001 | 0.09 | 1.180 | .127 |
|      |       |                |             | Fatigue level                    | −0.59 (−0.78 to −0.40) | 0.09 | −0.43 | 1.444 | <.001 |
|      |       |                |             | Depression                       | −5.69 (−11.70 to 0.32) | 3.01 | −0.13 | 1.508 | .063 |
|      |       |                |             | Anxiety                          | −2.96 (−5.90 to −0.02) | 1.47 | −0.14 | 1.615 | .048 |
|      |       |                |             | Social support                   | 0.23 (0.15 to 0.31) | 0.04 | 0.38 | 1.210 | <.001 |
|      |       |                |             | Physical activity                | 0.54 (−3.37 to 4.45) | 1.96 | 0.01 | 1.110 | .783 |

Abbreviations: CI, confidence interval; SE, standard error; VIF, variance inflation factor.
Table 8. Health-Related Biomarkers of the Total Sample and by the Amount of Physical Activity (Reported as Means ± SDs).

|                          | Total   | Less Active | More Active | Test Statistics | P   | r   |
|--------------------------|---------|-------------|-------------|----------------|-----|-----|
| CRP (mg/L)               | 3.39 ± 4.23 | 3.77 ± 4.51 | 2.93 ± 3.83 | 1384           | .163| −0.13|
| IL-6 (pg/mL)             | 1.33 ± 1.57 | 1.44 ± 1.54 | 1.20 ± 1.62 | 1260           | .090| −0.16|
| TNF-α (pg/mL)            | 2.07 ± 1.51 | 2.18 ± 1.90 | 1.93 ± 0.81 | 1617           | .933| −0.00|
| VEGF (pg/mL)             | 68.05 ± 70.43 | 68.71 ± 61.31 | 67.23 ± 81.08 | 1551           | .648| −0.04|
| IL1ra (pg/mL)            | 420.76 ± 290.07 | 458.65 ± 300.84 | 373.29 ± 271.41 | 1310           | .070| −0.17|
| Inflammatory index       | NA      | .10737 ± .9341 | −.13315 ± 10.706 | 1.269          | .207| 0.12|
| HRV acclimation (5 minutes) |        |             |             |                |     |     |
| Heart rate (bpm)         | 73.37 ± 9.38 | 74.98 ± 8.29 | 71.31 ± 10.34 | 2.085b         | .039| 0.19|
| Respiratory rate (bpm)   | 15.43 ± 4.69 | 15.86 ± 4.55 | 14.90 ± 4.87 | 1324           | .198| −0.12|
| rMSSD (ms)               | 21.98 ± 17.25 | 22.95 ± 19.59 | 20.72 ± 13.75 | 1497           | .785| −0.02|
| LFHF ratio               | 4.25 ± 5.39 | 3.51 ± 3.49 | 5.21 ± 7.06 | 1424           | .483| −0.06|
| HRV rest (5 minutes)     |         |             |             |                |     |     |
| Heart rate (bpm)         | 73.49 ± 9.20 | 75.09 ± 8.32 | 71.43 ± 9.94 | 2.120b         | .036| 0.19|
| Respiratory rate (bpm)   | 15.56 ± 4.87 | 15.99 ± 4.68 | 14.99 ± 5.10 | 1317           | .184| −0.12|
| rMSSD (ms)               | 21.98 ± 18.37 | 22.40 ± 19.97 | 21.45 ± 16.29 | 1515           | .867| −0.01|
| LFHF ratio               | 5.10 ± 6.97 | 3.75 ± 3.26 | 6.84 ± 9.66 | 1442           | .552| −0.05|

Abbreviations: CRP, C-reactive protein; IL-6, interleukin 6; TNF-α, tumor necrosis factor-α; VEGF, vascular endothelial growth factor; IL1ra, interleukin-1 receptor antagonist; HRV, heart rate variability; bpm, beats per minute; rMSSD, square root of the mean squared differences of successful N-N intervals; ms, milliseconds; LFHF, low frequency/high frequency.

aThe inflammatory index had an Eigenvalue ≥ 2.075. Eigenvalues ≥ 1 represent that the factor explains more variance that an inflammatory marker alone.

b t statistic. All other test statistics are reported as (U).

results are in concordance with other studies that also identified high rates of use of vitamins and supplements in cancer patients, varying from 67% to 91% of cancer patients. Interestingly, we observed that patients who were more physically active used half of the supplements used by their less-active peers. The more active patients tended to get their prescriptions from naturopathic physicians, which might suggest they more frequently seek treatment from naturopathic physicians. We hypothesize that greater QoL among more active patients could be related to these patients seeking less additional supplements for symptom management or improvement in well-being, and we suggest this hypothesis be tested in a future, longitudinal study.

In addition to supplements use, participants reported their previous use of CAM therapies. Massage, yoga, and acupuncture were most frequently utilized (75.2%, 66.1%, and 59.6%, respectively). We did not observe differences in the use of CAM therapies between groups. Compared with other studies, our sample was highly engaged in CAM therapies, which was expected, considering that our sample was selected by convenience from a pool of patients who were interested in enrolling in integrative therapies. By comparison, Liu and collaborators saw 39% use of manual therapies, including massage and acupressure, Frenkel and collaborators observed 10% use of massage therapy use and 16% of cancer patients engaged in Asian movement therapies, including yoga, tai chi, or Qi Gong, before enrolling in an integrative oncology clinic. A limitation of our analysis is that we queried the use of CAM therapies individually, and thus were unable to detect if patients were using multiple CAMs simultaneously.

We found that more physically active patients reported a better QoL than their less-active peers, specifically their physical and functional well-being. Others have reported similar associations in a case-control design, and the positive, causal effects of exercise interventions (eg, 6 months on an exercise program) on QoL in cancer patients has been confirmed by more robust study designs. More physically active patients also reported lower fatigue levels and fewer cancer-related physical symptoms, which aligns with prior reports of decreased fatigue among patients who exercised during their cancer treatment. However, another systematic review evaluated the effectiveness of exercise for cancer patient QoL and suggested that exercise does not perform better than standard care, though it does appear to reduce fatigue.

There were fewer borderline and clinical cases (according to the suggested cut points) of depression in the more physically active group. We also observed fewer cases of anxiety in the more physically active group, although the prevalence differences for anxiety did not reach statistical
significance between groups. While a handful of trials report positive associations and effects of PA on mental health in cancer patients, and that insufficient PA is associated with depression and anxiety, more robust evidence from systematic reviews of randomized controlled trials reported mild or insignificant changes for depression and anxiety.

We found that perceived social support was superior among more active patients, although the difference between groups was not statistically significant. In general, the overall social support of these patients (roughly 74, ranging from 72 to 78 points) was comparable to a prospective cohort that followed cancer patients since their diagnosis, with an overall social support score at baseline of 80.9 and decreased to 72 after 2 years.

Although differences between PA groups for cardiovascular and immune-related biomarkers were not statistically significant, patients who were more physically active generally had lower levels of inflammatory biomarkers. With regard to cardiac measures, heart rate was significantly lower in more active individuals, which is expected, considering that higher resting heart rate has been inversely associated with physical fitness. Interestingly, elevated resting heart rate has been associated with increased prospective risk of mortality and disease recurrence in cancer survivors, supporting the hypothesis that poor cardiovascular fitness, and related autonomic sequelae, may be important therapeutic targets in improving cancer-related outcomes. Our results also indicated that higher intensity of PA was associated with lower levels of inflammation, which corroborates recent evidence in cancer patients, and suggests that higher intensities of PA may be uniquely desirable to mitigate cancer- and treatment-related chronic inflammation in patient populations.

In a multivariable analysis, we also examined correlates of QoL, with a regression model indicating that age, fatigue, anxiety, and social support were the strongest independent correlates, explaining 71% of the variance in QoL. However, when added to the model with the other correlates, PA was no longer significantly associated with QoL, though this may have been related to the reduction in total sample size given missing data of other correlates entered in our model. Our findings are supported by a matched cohort study with breast cancer survivors, where the authors identified age as a significant predictor for general QoL assessed by the SF-36 questionnaire.

This study has strengths and limitations. One strength is that we were able to assess the individuals enrolling in the InspireHealth clinic as a whole, including sociodemographic, health history, physiological and psychological characteristics, and health-related behaviors. Our main objective was to describe patients who seek integrative care, and despite issues related to selection bias, we were able to do so. Nonetheless, our study had limitations, as well. The study design was cross-sectional, thus limiting causal analysis or interpretation. The sample was drawn by convenience; and therefore, it did not include cancer patients not seeking integrative care. Because all patients shared a similar interest in CIM, our results should be interpreted with caution and not necessarily extrapolated to the broader population of cancer patients. There is a possibility that patients with better QoL make time to exercise more often than those with poorer QoL, which may be a prediagnosis difference that persisted throughout their illness. Moreover, the InspireHealth clinic is located in Canada, and this is also a limiting factor in generalizing our findings to populations of other countries.

Regarding our analyses, there were some missing data, and such a limitation might have negatively affected power in the analyses, including the regression model. The instrument used to capture PA was a self-reported questionnaire. Although commonly used to capture leisure-time PA, we are aware of existing discrepancies between self-reported and objectively measures of PA. Other variables were also self-reported; for example, the use of medications and supplements, and its open-ended format allowed patients to omit identifying prescribers. The missing information accounted for 41.9% of all pharmacologics and 69.7% of all supplements. Furthermore, errors in memory recall could have biased these and other self-reported variables. Additionally, our physiological biomarker analyses were unadjusted for additional confounders, such as type of drug, stage of the disease, current treatment, depression, and anxiety. Finally, we did not analyze eating patterns or diet in our study, which is also an important health behavior.

Conclusion

We observed significant differences in self-reported physical and functional well-being, level of fatigue, physical symptoms associated with cancer, the prevalence of depression, and the use of supplements among patients who engaged in more versus less PA postdiagnosis. We observed positive associations between total and moderate PA and QoL, as well as negative associations between vigorous PA and inflammation. Gender, fatigue, anxiety, and social support were strong correlates of QoL. Considering the continuous growth of integrative care use globally, especially in Canada, our findings can inform health services and decision-makers how to optimize physical and functional well-being in cancer patients undergoing active treatment.

Acknowledgments

We are grateful to the staff of InspireHealth in Vancouver, British Columbia, Canada, and to the patients who participated in the study.
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: WJ is Executive Director of Samueli Integrative Health Programs.

Funding
The author(s) disclosed receipt of the following support for the research, authorship, and publication of this article: MTP: This work was supported by the National Institutes of Health, National Heart, Lung, and Blood Institute (5T32HL079891-13). JK: This work was also supported by the National Institutes of Health, National Heart, Lung, and Blood Institute (RO1HL126056) and the National Center for Advancing Translational Sciences (1TL1TR001443). Support was provided by The Lotte & John Hecht Memorial Foundation, Samueli Integrative Health Programs, and the University of California, San Diego Center of Excellence for Research and Training in Integrative Health.

ORCID iDs
Maira Tristão Parra https://orcid.org/0000-0002-5734-4272
Naghmeh Esmeaeli https://orcid.org/0000-0003-4516-7106
Jordan Kohl https://orcid.org/0000-0001-8546-2076
Stephen Klagholz https://orcid.org/0000-0001-5671-6129
Wayne Jonas https://orcid.org/0000-0001-8498-3849

References
1. World Health Organization. Cancer. https://www.who.int/cancer/en. Accessed July 17, 2019.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424. doi:10.3322/caac.21492
3. World Health Organization. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2016. Geneva, Switzerland: World Health Organization; 2018.
4. Statistics Canada. Table 13-10-0394-01 Leading causes of death, total population by age group. https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310039401. Accessed July 2, 2019.
5. World Health Organization. Global Action Plan for the prevention and control of noncommunicable diseases 2013-2020. https://www.who.int/nmh/events/ncd_action_plan/en/. Accessed July 17, 2019.
6. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220-241. doi:10.3322/caac.21149
7. Adams M, Jewell AP. The use of complementary and alternative medicine by cancer patients. Int Semin Surg Oncol. 2007;4:10. doi:10.1186/1477-7800-4-10
8. Santos JC, Pyter LM. Neuroimmunology of behavioral comorbidities associated with cancer and cancer treatments. Front Immunol. 2018;9:1195. doi:10.3389/fimmu.2018.01195
9. Armaiz-Pena GN, Cole SW, Lutgendorf SK, Sood AK. Neuroendocrine influences on cancer progression. Brain Behav Immun. 2013;30(suppl):S19-S25. doi:10.1016/j.bbi.2012.06.005
10. O’Higgins CM, Brady B, O’Connor B, Walsh D, Reilly RB. The pathophysiology of cancer-related fatigue: current controversies. Support Care Cancer. 2018;26:3353-3364. doi:10.1007/s00520-018-4318-7
11. Crosswell AD, Lockwood KG, Ganz PA, Bower JE. Low heart rate variability and cancer-related fatigue in breast cancer survivors. Psychoneuroendocrinology. 2014;45:58-66. doi:10.1016/j.psyneune.2014.03.011
12. Fagundes CP, Murray DM, Hwang BS, et al. Sympathetic and parasympathetic activity in cancer-related fatigue: more evidence for a physiological substrate in cancer survivors. Psychoneuroendocrinology. 2011;36:1137-1147. doi:10.1016/j.psyneuen.2011.02.005
13. Khosravi N, Stoner L, Farajivafa V, Hanson ED. Exercise training, circulating cytokine levels and immune function in cancer survivors: a meta-analysis. Brain Behav Immun. 2019;81:92-104. doi:10.1016/j.bbi.2019.08.187
14. LaVoy ECP, Fagundes CP, Danziger R. Exercise, inflammation, and fatigue in cancer survivors. Exerc Immunol Rev. 2016;22:82-93.
15. Aggarwal BB, Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol. 2009;9:351-369. doi:10.1016/j.coph.2009.06.020
16. DeNardo DG, Johansson M, Coussens LM. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 2008;27:11-18. doi:10.1007/s10555-007-9100-0
17. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72:1605-1621. doi:10.1016/j.bcp.2006.06.029
18. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-κB in development and progression of human cancer. Virchows Arch. 2005;446:475-482. doi:10.1007/s00428-005-1264-9
19. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 2003;17:2115-2117. doi:10.1096/fj.03-0329jfe
20. Qin Y, Auh S, Blokh L, Long C, Gagnon I, Hamann KJ. TNF-alpha induces transient resistance to Fas-induced apoptosis in eosinophilic acute myeloid leukemia cells. Cell Mol Immunol. 2007;4:43-52.
21. Chiang JK, Koo M, Kuo TBJ, Fu CH. Association between cardiovascular autonomic functions and time to death in patients with terminal hepatocellular carcinoma. J Pain Symptom Manage. 2010;39:673-679. doi:10.1016/j.jpainsymman.2009.09.014
22. Chiang JK, Kuo TBJ, Fu CH, Koo M. Predicting 7-day survival using heart rate variability in hospice patients with non-lung cancers. PLoS One. 2013;8:e69482. doi:10.1371/journal.pone.0069482
23. Duncan M, Moschopoulou E, Harrington E, et al. Review of systematic reviews of non-pharmacological interventions
to improve quality of life in cancer survivors. BMJ Open. 2017;7:e015860. doi:10.1136/bmjopen-2017-015860

24. Liu L, He X, Feng L. Exercise on quality of life and cancer-related fatigue for lymphoma survivors: a systematic review and meta-analysis. Support Care Cancer. 2019;27:4069-4082. doi:10.1007/s00520-019-04983-y

25. Hojman P, Gehl J, Christensen JF, Pedersen BK. Molecular mechanisms linking exercise to cancer prevention and treatment. Cell Metab. 2018;27:10-21. doi:10.1016/j.cmet.2017.09.015

26. Witt CM, Balneaves LG, Cardoso MJ, et al. A comprehensive definition for integrative oncology. J Natl Cancer Inst Monogr. 2017;2017(52). doi:10.1093/jncimonographs/lgx012

27. Greenlee H, Balneaves LG, Carlson LE, et al. Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. J Natl Cancer Inst Monogr. 2014;2014:346-358. doi:10.1093/jncimonographs/luo041

28. Grant SJ, Marthick M, Lacey J. Establishing an integrative oncology service in the Australian healthcare setting—the Chris O’Brien Lifehouse Hospital experience. Support Care Cancer. 2019;27:2069-2076. doi:10.1007/s00520-018-4460-2

29. Grant SJ, Hunter J, Seely D, Balneaves LG, Rossi E, Bao T. Integrative oncology: international perspectives. Integr Cancer Ther. 2019;18:1534735418823266. doi:10.1177/1534735418823266

30. Hilton L, Eifenbaum P, Jain S, Sprengel M, Jonas WB. Establishing an integrative oncology service: an example with the InspireHealth Clinic. Integr Cancer Ther. 2018;17:106-114. doi:10.1177/1534735416668017

31. Oken MM, Creech RH, Torrey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.

32. Kemmler G, Holzner B, Kopp M, et al. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. J Clin Oncol. 1999;17:2932-2940. doi:10.1200/JCO.1999.9.9.2932

33. Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32:705-714. doi:10.1016/0277-9536(91)90150-b

34. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361-370.

35. Yellen SB, Cell DF, Webster K, Bendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13:63-74.

36. Chang VT, Hwang SS, Feuerman M, Kasimis BS, Thaler HT. The Memorial Symptom Assessment Scale Short Form (MSAS-SF). Cancer. 2000;89:1162-1171. doi:10.1002/1097-0142(20000901)89:5<1162::aid-cncr26>3.0.co;2-y

37. Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. Can J Appl Sport Sci. 1985;10:141-146.

38. Kushi LH, Doyle C, McCullough M, et al. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2012;62:30-67. doi:10.3322/caac.20140

39. Redwine LS, Henry BL, Pung MA, et al. Pilot randomized study of a gratitude journaling intervention on heart rate variability and inflammatory biomarkers in patients with stage B heart failure. Psychosom Med. 2016;78:667-676. doi:10.1097/PSY.0000000000000316

40. Mills PJ, Taub PR, Lunde O, et al. Depressive symptoms in asymptomatic stage B heart failure with type II diabetic mellitus. Clin Cardiol. 2019;42:637-643. doi:10.1002/clc.23187

41. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996;93:1043-1065.

42. Vivonoeitics. VivoSense® [computer software] User Manual—Heart Rate Variability Professional Edition. Newport Beach, CA: Vivonoeitics; 2017.

43. Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104:815-840. doi:10.1093/jnci/djs207

44. Papadopoulos E, Mina DS. Can we HIIT cancer if we attack inflammation? Cancer Causes Control. 2018;29:7-11. doi:10.1007/s10552-017-0983-y

45. Alizadeh AM, Isanejad A, Sadighi S, Mardani M, Kalaghchi B, Hassan ZM. High-intensity interval training can modulate the systemic inflammation and HSP70 in the breast cancer: a randomized control trial. J Cancer Res Clin Oncol. 2019;145:2583-2593. doi:10.1007/s00432-019-02996-y

46. Kleckner IR, Kamen C, Cole C, et al. Effects of exercise on inflammation in patients receiving chemotherapy: a nationwide NCORP randomized clinical trial. Support Care Cancer. 2019;27:4615-4625. doi:10.1007/s00520-019-04772-7

47. Hack CC, Fasching PA, Fehm T, et al. Interest in integrative medicine among postmenopausal hormone receptor-positive breast cancer patients in the EvAluate-TM study. Integr Cancer Ther. 2017;16:165-175. doi:10.1177/1534735416668575

48. Liu R, Chang A, Reddy S, Hecht FM, Chao MT. Improving patient-centered care: a cross-sectional survey of prior use and interest in complementary and integrative health approaches among hospitalized oncology patients. J Altern Complement Med. 2016;22:160-165. doi:10.1089/acm.2015.0061

49. Frenkel M, Cohen L, Peterson N, Palmer JL, Swint K, Bruera E. Integrative medicine consultation service in a comprehensive cancer center: findings and outcomes. Integr Cancer Ther. 2016;15:1034-1065.

50. Yellen SB, Cella DF, Moser DK, et al. The Functional Assessment of Cancer Therapy-General. J Clin Oncol. 2000;18:387-400. doi:10.1200/JCO.2000.09.001

51. Pinto-Riviere F, Friedenreich CM, Courneya KS, et al. Physical activity, biomarkers, and cancer outcomes in Canadian cancer survivors: a systematic review. CMAJ. 2009;181:1023-1029. doi:10.1503/cmaj.090928

52. Fremd C, Hack CC, Schneeweiss A, et al. Use of complementary and integrative medicine among German breast cancer patients, and reasons for use. Support Care Cancer. 2019;27:2069-2076. doi:10.1007/s00520-018-4460-2

53. Mills PJ, Taub PR, Lunde O, et al. Depressive symptoms in asymptomatic stage B heart failure with type II diabetic mellitus. Clin Cardiol. 2019;42:637-643. doi:10.1002/clc.23187

54. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996;93:1043-1065.

55. Vivonoeitics. VivoSense® [computer software] User Manual—Heart Rate Variability Professional Edition. Newport Beach, CA: Vivonoeitics; 2017.

56. Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104:815-840. doi:10.1093/jnci/djs207
patients: predictors and implications for patient care within the PRAEGNANT study network. Arch Gynecol Obstet. 2017;295:1239-1245. doi:10.1007/s00404-017-4348-2

53. Farris MS, Kopciuk KA, Courneya KS, McGregor SE, Wang Q, Friedenreich CM. Associations of postdiagnosis physical activity and change from prediagnosis physical activity with quality of life in prostate cancer survivors. Cancer Epidemiol Biomarkers Prev. 2017;26:179-187. doi:10.1158/1055-9965.EPI-16-0465

54. Segal R, Zwaal C, Green E, Tomasono JR, Loblaw A, Petrella R. Exercise for people with cancer: a clinical practice guideline. Curr Oncol. 2017;24:40-46. doi:10.3747/co.24.3376

55. Loughney LA, West MA, Kemp GJ, Grocott MP, Jack S. Facilitators of exercise experienced by cancer survivors: a mixed methods systematic review. Support Care Cancer. 2018;26:685-700. doi:10.1007/s00520-017-3964-5

56. Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev. 2012;(8):CD008465. doi:10.1002/14651858.CD008465.pub2

57. Loughney LA, West MA, Kemp GJ, Grocott MP, Jack S. Exercise interventions for people undergoing multimodal cancer treatment that includes surgery. Cochrane Database Syst Rev. 2018;(12):CD012280. doi:10.1002/14651858.CD012280.pub2

58. Chen HM, Tsai CM, Wu YC, Lin KC, Lin CC. Randomised controlled trial on the effectiveness of home-based walking exercise on anxiety, depression and cancer-related symptoms in patients with lung cancer. Br J Cancer. 2015;112:438-445. doi:10.1038/bjc.2014.612

59. Fisher HM, Jacobs JM, Taub CJ, et al. How changes in physical activity relate to fatigue interference, mood, and quality of life during treatment for non-metastatic breast cancer. Gen Hosp Psychiatry. 2017;49:37-43. doi:10.1016/j.genhosppsych.2017.05.007

60. Branstrom R, Petersson LM, Saboonchi F, Wennman-Larsen A, Alexanderson K. Physical activity following a breast cancer diagnosis: implications for self-rated health and cancer-related symptoms. Eur J Oncol Nurs. 2015;19:680-685. doi:10.1016/j.ejon.2015.04.008

61. Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical activity for women with breast cancer after adjuvant therapy. Cochrane Database Syst Rev. 2018;(1):CD011292. doi:10.1002/14651858.CD011292.pub2

62. Peddle McIntyre CJ, Singh F, Thomas R, Newton RU, Galvão DA, Cavalheri V. Exercise training for advanced lung cancer. Cochrane Database Syst Rev. 2019;(2):CD012685. doi:10.1002/14651858.CD012685.pub2

63. Haviland J, Sodergren S, Calman L, et al. Social support following diagnosis and treatment for colorectal cancer and associations with health-related quality of life: Results from the UK ColoRectal Wellbeing (CREW) cohort study. Psychooncology. 2017;26:2276-2284. doi:10.1002/pon.4556

64. Jensen MT, Suadicani P, Hein IHO, Gyntelberg F. Elevated resting heart rate, physical fitness and all-cause mortality: a 16-year follow-up in the Copenhagen Male Study. Heart. 2013;99:882-887. doi:10.1136/heartjnl-2012-303375

65. Park J, Kim JH, Park Y, et al. Resting heart rate is an independent predictor of advanced colorectal adenoma recurrence. PLoS One. 2018;13:e0193753. doi:10.1371/journal.pone.0193753

66. Anker MS, Ebner N, Hildebrandt B, et al. Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non-small cell lung cancer: results of a prospective cardiovascular long-term study. Eur J Heart Fail. 2016;18:1524-1534. doi:10.1002/ejhf.670

67. Andersen MR, Sweet E, Hager S, Gaul M, Dowd F, Standish LJ. Use of integrative oncology, involvement in decision-making, and breast cancer survivor health-related quality of life in the first 5 years postdiagnosis. Integr Cancer Ther. 2018;17:636-645. doi:10.1177/153473541762543

68. Wagoner CW, Choi SK, Deal AM, et al. Establishing physical activity in breast cancer: self-report versus activity tracker. Breast Cancer Res Treat. 2019;176:395-400. doi:10.1007/s10549-019-05263-3

69. Colley RC, Butler G, Garriguet D, Prince SA, Roberts KC. Comparison of self-reported and accelerometer-measured physical activity in Canadian adults. Health Rep. 2018;29:3-15.

70. Keshet Y, Schiff E, SamuelNS, Ben-Arye E. Giving voice to cancer patients: assessing non-specific effects of an integrative oncology therapeutic program via short patient narratives. Psychooncology. 2015;24:169-174. doi:10.1002/pon.3621

71. Smith CA, Hunter J, Delaney GP, et al. Integrative oncology and complementary medicine cancer services in Australia: findings from a national cross-sectional survey. BMC Complement Altern Med. 2018;18:289. doi:10.1186/s12906-018-2357-8

72. Zollman C, Walther A, Seers HE, Jolliffe RC, Polley MJ. Applying new models of care to meet patient needs in integrative oncology. J Altern Complement Med. 2018;24:1010-1011. doi:10.1089/acm.2018.0151

73. Canizares M, Hogg-Johnson S, Gignac MAM, Glazier RH. Integrative oncology therapeutic program via short patient narratives. J Natl Cancer Inst Monogr. 2017;2017(52). doi:10.1093/jncimono/lcx002

74. Drhuva A, Atreya CE, Chao MT. Applying new models of care to meet patient needs in integrative oncology. J Altern Complement Med. 2018;24:1010-1011. doi:10.1089/acm.2018.0151

75. Canizes M, Hogg-Johnson S, Gignac MAM, Glazier RH. Integrative oncology therapeutic program via short patient narratives. J Natl Cancer Inst Monogr. 2017;2017(52). doi:10.1093/jncimono/lcx002